19:52 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Eylea meets 52-week endpoint in Phase III for diabetic retinopathy subset

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said both dosing schedules of Eylea aflibercept met the 52-week primary endpoint in the Phase III PANORAMA trial for early intervention of non-proliferative diabetic retinopathy without diabetic macular edema (DME). The...
00:23 , Oct 26, 2018 |  BC Extra  |  Company News

FDA setback, positive data for Regeneron’s Eylea

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares slipped on Thursday, falling $14.45 to $336.94, after the company reported a regulatory delay for a prefilled syringe of Eylea aflibercept alongside positive data for the eye drug. The company...
16:31 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Regeneron's Eylea clears first Phase III hurdle in diabetic retinopathy subset

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said Eylea aflibercept met the first of two primary endpoints in the Phase III PANORAMA trial to treat non-proliferative diabetic retinopathy without diabetic macular edema (DME). The company plans to submit...
21:31 , Mar 19, 2018 |  BC Extra  |  Clinical News

Eylea clears first Phase III hurdle in diabetic retinopathy subset

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said Eylea aflibercept met the first of two primary endpoints in the Phase III PANORAMA trial to treat non-proliferative diabetic retinopathy without diabetic macular edema (DME). The company plans to submit...
19:34 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest NMDA receptor antagonists could help treat autism caused by MEF2C haploinsufficiency. In an MEF2C-haploinsufficient mouse model of autism, NitroSynapsin, a memantine-based NMDA receptor antagonist, increased total hippocampal neurons and decreased...
00:23 , Nov 17, 2017 |  BC Extra  |  Preclinical News

Memantine-based NMDA receptor antagonist could help treat autism

A study published in Nature Communications identified myocyte enhancer factor 2C (MEF2C) mutations as a source of abnormal brain development and function and suggests an NMDA receptor antagonist could help treat autism. MEF2C regulates several...
03:20 , May 6, 2017 |  BioCentury  |  Strategy

mDx blueprint

Thanks to a well-planned robust pivotal trial and a dose of good timing, Cologuard from Exact Sciences Corp. is enjoying one of the steepest launch trajectories of any molecular diagnostic. After 10 quarters of sales,...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

Natera, Sequenom, Thermo Fisher, Roche diagnostic news

The U.S. Supreme Court declined to review a lower court decision invalidating U.S. Patent No. 6,258,540 covering prenatal diagnosis with nucleic acid analysis used in Sequenom’s MaterniT21 Plus laboratory-developed test. Sequenom had asked SCOTUS to...
07:00 , Oct 5, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/2 cls Celgene Corp. (NASDAQ:CELG) JPMorgan Cory Kasimov Upgrade Overweight (from neutral) 7% $116.44 Kasimov upgraded on valuation after the...
01:19 , Jul 23, 2015 |  BC Extra  |  Financial News

Sequoia backs MedGenome's $20M series B

MedGenome Inc. (San Francisco, Calif.) raised $20 million in a series B round from Sequoia Capital. The company operates a next-generation sequencing lab in India, and markets diagnostic tests for cancer and metabolic diseases as...